scholarly journals COMBINATION THERAPY IN THE MANAGEMENT OF ARTERIAL HYPERTENSION: EFFECTIVENESS OF THE LERCANIDIPINE AND ENALAPRIL COMBINATION

2013 ◽  
Vol 12 (5) ◽  
pp. 75-80
Author(s):  
L. O. Minushkina

This review presents the evidence on the benefits of fixed-dose combination therapy for arterial hypertension management. The focus is on the combination of a third-generation dihydropyridine calcium antagonist lercanidipine and an ACE inhibitor enalapril. Lercanidipine is characterised by high vascular selectivity and lipophilicity, good antihypertensive effectiveness, and prolonged, gradually developing therapeutic effects. Literature data on the effectiveness of the lercanidipine-enalapril combination are presented. This combination facilitates a marked reduction in blood pressure levels, which is particularly relevant for elderly patients and patients with diabetes mellitus or obesity. The combination of pharmacologic effects of lercanidipine and enalapril provides additional benefits in terms of organ protection and reduction of adverse effects of the antihypertensive treatment. 

Author(s):  
Z. M. Galeyeva ◽  
A. S. Galyavich ◽  
L. V. Baleyeva ◽  
E. G. Safina ◽  
O. V. Sorokina

The article presents data about the prevalence and expected prognosis for arterial hypertension. Emphasis is placed on the selection of antihypertensive therapy in elderly patients. The features concerning the positive effect of the calcium channelblocking agent — amlodipine, thiazid­like diuretic — indapamide retard in the form of monotherapy and a combination of the above drugs on the course and prognosis of arterial hypertension in elderly patients are investigated. A clinical example of the use of the fixed dose combination amlodipine + indapamide retard is also introduced.


2013 ◽  
Vol 12 (4) ◽  
pp. 62-66
Author(s):  
N. E. Gavrilova ◽  
R. G. Oganov

Arterial hypertension (AH) is one of the most important problems of the modern medicine, due to its exceptionally high prevalence. This study focused on effectiveness and safety of the diuretic-based combination therapy among patients aged >18 years (1476 men and 2989 women) with a clinical diagnosis of Stage 1–3 AH. All patients received fixed-dose combination therapy with atenolol and chlorthalidone. The findings from the TRUST study have confirmed safety and effectiveness of the fixed-dose combination of atenolol and chlorthalidone. 


2013 ◽  
Vol 12 (3) ◽  
pp. 72-77 ◽  
Author(s):  
E. I. Astashkin ◽  
M. G. Glezer

This review presents the modern views on the effectiveness of water-soluble angiotensin-converting enzyme (ACE) antagonists and calcium antagonists (CA), as monotherapy or as fixed-dose combination therapy, in the treatment of arterial hypertension (AH). The results of the X-ray structural analysis of crystal ACE-lisinopril complexes suggest a highly selective, strong inhibitory effect of lisinopril on various ACE forms of the hormonal renin-angiotensin-aldosterone system and tissue renin-angiotensin systems. The association between specific action mechanisms and therapeutic effects in hypertension is analysed for a third-generation CA amlodipine. The benefits of a fixed-dose combination medication Ekvator (amlodipine 5 mg plus lisinopril 10 mg) in hypertension are described, including its synergetic protective effects. 


1997 ◽  
Vol 90 (Supplement) ◽  
pp. 10-11
Author(s):  
William J. Elliott

Sign in / Sign up

Export Citation Format

Share Document